Literature DB >> 15540708

Impaired renal allograft, but not patient survival, in patients with antibodies to hepatitis C virus.

L Giblin1, M R Clarkson, P J Conlon, J J Walshe, P O'Kelly, D Hickey, D Little, M Keoghan, J Donohoe.   

Abstract

BACKGROUND: The impact of hepatitis C virus (HCV) infection in renal transplant patients is controversial and there are no data on the outcome of renal transplantation in this sub-group of Irish patients. AIM: To examine the outcome of renal transplantation in patients with hepatitis C.
METHODS: We examined the outcome of first grafts from renal transplant patients with hepatitis C antibody positive and compared them to a control group. During this period, 24 HCV positive patients received 33 grafts. All were treated with standard immunosuppression.
RESULTS: Graft survival rate was less in the HCV positive cases (p=0.0087). Graft survival at 1 year was 75% in the HCV positive group versus 85% in the HCV negative group, 40% versus 62% at 5 years and 14% compared with 40% at 10 years. Patient survival was similar in both groups (p=0.78). Patient survival at 1 year was 96% versus 94%, 87% versus 80% at 5 years and 70% in both groups at 10 years.
CONCLUSION: In the Irish renal transplant population, the presence of hepatitis C antibodies, before or after transplantation is associated with worse long-term graft, but not patient survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15540708     DOI: 10.1007/bf02914562

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  10 in total

Review 1.  Transplantation in the patient with hepatitis C.

Authors:  José M Morales; Josep M Campistol
Journal:  J Am Soc Nephrol       Date:  2000-07       Impact factor: 10.121

Review 2.  Hepatitis C epidemiology.

Authors:  D L Thomas
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

3.  Impact of hepatitis B and C virus on kidney transplantation outcome.

Authors:  P Mathurin; C Mouquet; T Poynard; C Sylla; H Benalia; C Fretz; V Thibault; J F Cadranel; B Bernard; P Opolon; P Coriat; M O Bitker
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

Review 4.  Hepatitis C virus infection in dialysis and renal transplantation.

Authors:  B J Pereira; A S Levey
Journal:  Kidney Int       Date:  1997-04       Impact factor: 10.612

Review 5.  Hepatitis C virus infection in Eastern Europe.

Authors:  N V Naoumov
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

6.  Impaired kidney transplant survival in patients with antibodies to hepatitis C virus.

Authors:  M A Gentil; J L Rocha; G Rodríguez-Algarra; P Pereira; R López; G Bernal; J Muñoz; M Naranjo; J Mateos
Journal:  Nephrol Dial Transplant       Date:  1999-10       Impact factor: 5.992

7.  Outcome of renal graft recipients with hepatitis C virus infection.

Authors:  A Rodrigues; T Morgado; A C Henriques; A M Sarmento; M Pereira; S Guimarãcs
Journal:  Transpl Int       Date:  1996       Impact factor: 3.782

8.  Lower prevalence of anti-hepatitis C antibody in dialysis and renal transplant patients in Ireland.

Authors:  P J Conlon; J J Walshe; E G Smyth; E B McNamara; J Donohoe; M Carmody
Journal:  Ir J Med Sci       Date:  1993-04       Impact factor: 1.568

Review 9.  Hepatitis C in organ transplantation: its significance and influence on transplantation policies.

Authors:  B J Pereira
Journal:  Curr Opin Nephrol Hypertens       Date:  1993-11       Impact factor: 2.894

10.  The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation.

Authors:  B J Periera; T L Wright; C H Schmid; A S Levey
Journal:  Transplantation       Date:  1995-10-27       Impact factor: 4.939

  10 in total
  1 in total

1.  Hepatic dysfunction in kidney transplant recipients: prevalence and impact on graft and patient survival.

Authors:  Osama A Gheith; Mohamed A Saad; Ahmed A Hassan; Salem A-Eldeeb; Amgad E-El Agroudy; Hussein Sheashaa; Mohamed A Ghoneim
Journal:  Clin Exp Nephrol       Date:  2007-12-21       Impact factor: 2.801

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.